Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

This publication has 31 references indexed in Scilit:

• Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
  European Urology, 2009
• Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
  Journal of Clinical Oncology, 2008
• Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
  Cancer Research, 2008
• Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
  Proceedings of the National Academy of Sciences, 2007
• On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing
  Cancer and Metastasis Reviews, 2007
• Angiogenesis: an organizing principle for drug discovery?
  Nature Reviews Drug Discovery, 2007
• VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
  Cell, 2006
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
  Nature, 2005
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
  Published by Elsevier ,2005
• Modulation of tumor angiogenesis by stem cell factor.
  2000